Table 2. Estimated risk of subsequent serous carcinoma by serous borderline tumor gene mutation.
| Gene mutation | Total number of women | Number of women with subsequent serous carcinoma | Estimated median time to progression† (years) | HR (95% CI)* | p-value |
|---|---|---|---|---|---|
| Wildtype | 54 | 12 | 9.2 | 1.00 | - |
| BRAF | 52 | 22 | 19.7 | 0.27 (0.08 – 0.93) | 0.038 |
| KRAS | 95 | 5 | 14.4 | 1.00 (0.45 – 2.23) | 0.99 |
†time to progression derived using the Aalen-Johansen estimator.
*adjusted for age and stage (i.e. presence/absence of implants).